Introduction {#s1}
============

Qing-Kai-Ling injection (QKLI), a notable antipyretic preparation, is derived from Angong Niuhuang pills (ANP). ANP is a famous ancient Chinese patent medicine for the treatment of "febrile disease," and has been used across Asia, especially in China, for treating stroke, encephalitis and meningitis ([@B7]) for hundreds of years. For containing heavy metal (realgar and cinnabar), ANP is forbidden in the USA and European countries ([@B19]; [@B20]). As an extract of ANP without heavy metal ([@B31]), Qing-Kai-Ling (QKL) is widely used for the treatment of the upper respiratory inflammation, pneumonia, viral encephalitis and high fever ([@B10]) and listed in the Chinese Pharmacopoeia ([@B24]). Its components include Isatidis Radix (*Isatis tinctoria L.*), Lonicerae japonicae Flos (*Lonicera japonica* Thunb.), Gardeniae Fructus (*Gardenia jasminoides* J.Ellis), powdered buffalo horn, Concha Margaritifera Usta, cholic acid, hyodeoxycholic acid and baicalin. Perhaps the change in the traditional drug-delivery way (p.o.) brings increasing rapidly cases of adverse drug reaction (ADR) ([@B18]), and an alarm over QKLI-caused potential risks in patients was released by the Chinese National Center for Adverse Drug Reaction Monitoring in June 2008 and April 2009, respectively ([@B22]; [@B23]). In fact, QKLI is the second leading cause of ADRs induced by traditional Chinese medicine injections ([@B36]).

Immediate hypersensitivity reaction (IHR) can be divided into allergic- and non-allergic (NA)-mediated ([@B13]), while "anaphylaxis" is reserved for severe IHR ([@B14]). Drugs are the most common anaphylaxis triggers in adults ([@B3]). Among QKLI-induced ADRs, IHR accounted for the largest proportion ([@B38]). Accordingly, many researchers have focused on QKLI-induced IHR (QKLI-IHR). Some researchers speculated that QKLI caused allergic-IHRs based on the increased total IgE (tIgE) level in the serum of the QKLI-caused anaphylaxis patients ([@B37]), while others thought that QKLI-IHR was a non-immune mediated reaction by virtue of the unchanged plasma tIgE level in Beagle dogs treated with QKLI ([@B33]). Seemingly, QKLI can lead to the degranulation of effector cells (e.g., RBL-2H3, etc.) directly ([@B5]; [@B6]). But basic secretagogues \[e.g., compound 48/80 (C48/80) and substance P, etc.\] activate human mast cells degranulation through a single membrane receptor MrgprX2, whose orthologue in murine is MrgprB2 ([@B11]; [@B21]; [@B2]). As a rat basophilic leukemia cell line, RBL-2H3 cannot respond to C48/80 owing to the lack of these endogenous receptors ([@B16]; [@B27]), which is in agreement with our observational results. Thus, the attribution of QKLI-IHR and its underlying mechanisms are far from clear. The present study indicates that QKLI can directly activate complement-derived anaphylatoxin 3 (C3), which might subsequently stimulate its effector cells (e.g., mast cells and basophils) ([@B1]), thus releasing histamine to cause IHRs.

Materials and Methods {#s2}
=====================

Materials and Reagents {#s2_1}
----------------------

Commercial QKLI (Batch nos. 16020204, 16020205, and 16020206) and its eight raw materials were provided by Yisheng Pharmaceutical Co., Ltd. (Ji'an, Jilin, China) and authenticated by the Quality Controller Guilan Ding according to the Chinese Pharmacopoeia ([@B24]). Four intermediate fractions in QKLI (F1, the extract of powdered buffalo horn and margaritifera concha; F2, the extract of Gardeniae Fructus; F3, the extract of Isatidis Radix; F4, the extract of Lonicerae japonicae Flos) were prepared according to the Chinese Pharmacopoeia ([@B24]). The used QKLI in this study is the mixture of three batches products. C48/80, 4-Methylumbelliferyl N-acetyl-β-D-glucosaminide, propranolol, triprolidine, CV3988, and SB290157 were purchased from Sigma-Aldrich (St Louis, MO, USA). PMX53 was from TOCRIS Bioscience (Bristol, UK). Rehydragel^®^ aluminum adjuvant was from General Chemical (Parsippany, NJ, USA). Mouse total IgE (tIgE) ELISA kit was from Biolegend Co. (San Diego, CA, USA). Human C3a ELISA kit was from BD Biosciences (San Diego, CA, USA). Shrimp tropomyosin (ST) from *Metapenaeus ensis* was prepared as we previously described ([@B8]). Normal human serum was obtained from Solarbio life sciences Co. (Beijing, China).

HPLC Analysis {#s2_2}
-------------

Commercial QKLI was assayed by a Waters HPLC system. A highresolution HPLC column (Tnature C18, 250 mm × 4.6 mm, 5 μm) were used. Mobile phase A was 0.1% v/v formic acid in water and mobile phase B was acetonitrile. The flow rate is 1 ml/min. A gradient of mobile phase A is 0--5 min (0%--2%), 5--8 min (2%--10%), 8--50 min (10%--30%) and 50--60 min (30%--100%). The UV spectrophotometer detector was set at 235 nm.

Ethics Statement {#s2_3}
----------------

All the animal experiments were carried out according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Care and Use Committee, Institute of Medicinal Plant Development of Chinese Academy of Medical Sciences. Anesthetic drugs and all other necessary measures were used to reduce animal suffering during experimental procedures.

Cells and Animals {#s2_4}
-----------------

The human mast cell line LAD2 (from Michael D. Gershon, MD, Columbia University, USA) was a gift from Prof. Renshan Sun (the Third Military Medical University, Chongqing, China). Balb/c mice (female, 18--20 g) were purchased from Vital River Experimental Animal Services (Beijing, China) and housed in an SPF laboratory under standard temperature (22--24°C) and humidity (45%--65%) conditions with a 12 h light/dark cycle and standard pallet diet and water ad libitum. Primary abdominal mast cells were obtained from Balb/c mice.

Measurement of Serum tIgE {#s2_5}
-------------------------

Balb/c mice were injected (i.p.) weekly with aluminum adjuvant (100 μl/mouse) containing QKLI (50 μl/mouse) or ST (60 μg/mouse). ST was used as a positive control allergen. The negative control mice were only treated with aluminum adjuvant. Five weeks later, the mice were euthanized and the serum was collected for the assay. Serum tIgE level was determined by using a commercial ELISA kit according to the assay protocol.

β-Hexosaminidase Release Assay {#s2_6}
------------------------------

To determine the direct effect of QKLI on cell degranulation, LAD2 cells (5 × 10^4^ cells/well) or mouse peritoneal mast cells (1 × 10^6^ cells/well) were seeded in the 96-well plates and treated with QKLI at 37°C for 1.5 h. To evaluate the inhibitory effect of QKLI on C48/80-induced degranulation, the cells were pretreated with QKLI for 30 min followed by adding C48/80 (10 μg/ml) for further 1.5 h incubation. 30 μl of the supernatant was transferred to a 96-well black flat-bottom plate accompany with 50 μl of substrate solution (0.57 mg/ml 4-Methylumbelliferyl N-acetyl-β-D-glucosaminide in the buffer contained 133 mM sodium citrate and 133 mM NaCl, pH 4.3). The reaction proceeded at 37°C for 1.5 h and was stopped by adding stop buffer (50 mM glycine and 5 mM EDTA-Na2, pH 10.5; 200 μl/well). Fluorescence was determined with a fluorescence microplate reader at λex 355 nm and λem 460 nm ([@B8]).

Evans Blue Extravasation Assay {#s2_7}
------------------------------

Evans Blue extravasation in mice hind paws was measured as previously described ([@B21]). Briefly, 15 min after induction of anesthesia (50 mg/kg of pentobarbital), mice were intraplantarly (left paw) injected with 7 μl of QKLI. The right paw was injected with 7 μl of NS. Five minutes later, the mice were injected (i.v.) with 100 μl of 6.25 mg/ml Evans Blue. Thirty minutes later, the mice were euthanized. The paw tissues were collected and weighed. Evans Blue in the paw tissues were extracted by formamide at 60°C for 24 h. The OD values were read at 620 nm. The concentration of the dye in the paw tissues was calculated by the standard curve of the Evans Blue dye, and the dye content was expressed in microgram per gram of tissue.

Anaphylactic Shock Assay {#s2_8}
------------------------

Anaphylactic shock was assessed by rectal thermometry ([@B25]). To increase the severity of anaphylaxis ([@B30]; [@B17]), the mice were pretreated (i.v.) with propranolol (35 μg/mouse). Twenty minutes later, the mice were challenged (i.p.) with normal saline (NS) or QKLI (100 μl/mouse). Thirty minutes later, the rectal temperature was measured. For the antagonist experiment, CV3988 (a PAF antagonist, 0.337 μmol/mouse) or triprolidine (an H1 antagonist, 0.64 μmol/mouse) was injected (i.p.) into the mice 10 min before the propranolol pretreatment.

Complement Activation Assay *In Vitro* {#s2_9}
--------------------------------------

The human serum (100 μl, 1:500 dilution) was mixed with 4 μl of CaCl~2~ (1 M), 4 μl of MgCl~2~ (1 M), and 10 μl of test substances, and then incubated at 37°C. After 20 min, the reaction was stopped using 22 μl of EDTA (0.5 M, pH 8.0) and cooling to 0°C. Tween-80 was used as a positive control ([@B34]). The level of C3a in the plasma was determined using a commercial ELISA kit according to the manufacturer's instructions.

Statistical Analysis {#s2_10}
--------------------

Data are expressed as the means ± SD from at least three independent experiments and were analyzed by a one-way analysis of variance (ANOVA). A Student *t*-test was used when only two groups were compared. A difference with a *P*-value \< 0.05 was considered statistically significant.

Results {#s3}
=======

Fingerprint of QKLI {#s3_1}
-------------------

The main component profiles of QKLI were analyzed via HPLC-UV. The retention time values of the identified compounds were compared with that of the reference substances. Nine components (uridine, adenosine, guanosine, neochlorogenic acid, chlorogenic acid, caffeic acid, geniposide, baicalin, and 4,5-Di-O-caffeoylquinic acid) in QKLI were identified and their structures had also been shown ([**Figure 1**](#f1){ref-type="fig"}).

![Chromatogram fingerprint of Qing-Kai-Ling Injection.](fphar-10-01524-g001){#f1}

QKLI Fails to Induce IgE-Mediated IHR but Can Cause Non-Allergic IHR {#s3_2}
--------------------------------------------------------------------

IgE-mediated IHRs are the most common allergic-IHRs ([@B26]). To amplify the possible T helper 2 (Th2) response, the aluminum adjuvant was used during mouse immunization. Five weeks after intraperitoneal immunization, serum tIgE level was robustly elevated by ST, while QKLI failed to increase serum tIgE ([**Figure 2A**](#f2){ref-type="fig"}), indicating that QKLI-IHR is not mediated by IgE. Next, we evaluated whether QKLI could induce non-allergic IHR (NA-IHR). The local effect of QKLI on microvascular permeability was determined using the Evans Blue extravasation assay. As shown in [**Figure 2B**](#f2){ref-type="fig"}, QKLI significantly induced vasopermeability increase after the first intraplantar injection, demonstrating that QKLI-IHR was non-immune-mediated.

![QKLI fails to induce IgE-mediated IHRs but can cause NA-IHRs. **(A)** QKLI failed to elevate mouse serum tIgE. Mice were injected weekly (i.p.) with aluminum adjuvant (100 μl/mouse) containing QKLI (50 μl/mouse) or ST (60 μg/mouse). Five weeks later, the serum tIgE level was determined using a commercial ELISA kit. ^\*\*^ *P* \< 0.01 *vs.* NS. **(B)** QKLI induced vasopermeability increase after the first intraplantar injection. Fifteen minutes after induction of anesthesia (50 mg/kg of pentobarbital), mice were intraplantarly (left paw) injected with 7 μl of QKLI. The right paw was injected with 7 μl of NS. Five minutes later, the mice were injected (i.v.) with 100 μl of 6.25 mg/ml Evans Blue. Thirty minutes later, the mice were euthanized. The paw tissues were collected and weighed. Evans Blue in the paw tissues were extracted by formamide at 60°C for 24 h. The OD values were read at 620 nm. The concentration of the dye in the paw tissues was calculated by the standard curve of the Evans Blue dye, and the dye content was expressed in microgram per gram of tissue. ^\*\*^ *P* \< 0.01 *vs.* NS. QKLI, Qing-Kai-Ling Injection; IHR, immediate hypersensitivity reaction; NA-IHR, non-allergic IHR; tIgE, total IgE; NS, normal saline.](fphar-10-01524-g002){#f2}

Histamine H1 Receptor Antagonist Counters QKLI Induced NA-Anaphylaxis {#s3_3}
---------------------------------------------------------------------

Considering that QKLI was capable of causing anaphylaxis clinically ([@B22]; [@B23]), the effect of QKLI on mouse rectal temperature was evaluated after a single injection (i.p.). Propranolol, which does not induce shock by itself, was used for increasing the severity of QKLI-induced anaphylaxis ([@B30]; [@B17]). As shown in [**Figure 3**](#f3){ref-type="fig"}, C48/80 and QKLI contributed to obvious hypothermia in propranolol-pretreated mice.

![QKLI-induced hypothermia can be countered by triprolidine in propranolol-pretreated mice (n = 8). Triprolidine (0.64 μmol/mouse) or NS was injected (i.p.) into the mice. Ten minutes later, the mice were pretreated (i.v.) with propranolol (35 μg/mouse). Twenty minutes later, the mice were injected (i.p.) with NS or QKLI (100 μl/mouse). The rectal temperature was measured 30 min later. ^\*^ *P* \< 0.05 and ^\*\*^ *P* \< 0.01. QKLI, Qing-Kai-Ling Injection; NS, normal saline.](fphar-10-01524-g003){#f3}

Mast cells, basophils, and macrophages contribute predominantly to the pathogenesis of anaphylaxis through their secretion of histamine or/and PAF ([@B25]; [@B32]). Thus, we used a PAF antagonist CV3988 and a histamine H1 receptor antagonist triprolidine for blocking QKLI-caused hypothermia. As a result, QKLI-induced anaphylaxis was not affected by CV3988 (data not shown), but significantly countered by triprolidine ([**Figure 3**](#f3){ref-type="fig"}), indicating that histamine, rather than PAF, was the principal effector in QKLI-caused NA-anaphylaxis.

QKLI Triggers NA-IHR by Activating Anaphylatoxin C3 {#s3_4}
---------------------------------------------------

Given that histamine is mainly released by the activated mast cells ([@B4]), we firstly determined whether QKLI could directly promote mast cell degranulation. As shown in [**Figure 4A**](#f4){ref-type="fig"}, 10 μg/ml of C48/80 evoked a markedly β-hexosaminidase release in both human LAD2 cells and mouse peritoneal mast cells, while QKLI could not induce mast cell degranulation. And not only that, it can dampen C48/80-induced degranulation concentration-dependently in LAD2 cells ([**Figure 4B**](#f4){ref-type="fig"}) without cytotoxicity (data not shown), showing a potent mast cell stabilization effect.

![QKLI-induced NA-IHRs is mediated by C3a. **(A)** Effect of QKLI on the β-hexosaminidase release in mouse peritoneal mast cells and LAD2 cells. Cells were treated with QKLI at the indicated concentrations. Supernatant β-hexosaminidase level was determined 1.5 h later. C48/80 (10 μg/ml) was used as a positive control. ^\#\#^ *P* \< 0.01 *vs.* NS group. **(B)** QKLI decreased C48/80-induced β-hexosaminidase release in LAD2 cells. Cells were pretreated with QKLI for 30 min followed by adding C48/80 (10 μg/ml). Supernatant β-hexosaminidase level was determined 1.5 h later. ^\#\#^ *P* \< 0.01 *vs.* NS group and ^\*\*^ *P* \< 0.01 *vs.* C48/80 alone. **(C)** QKLI-induced Evans Blue extravasation was attenuated by SB290157 but not PMX53 (n = 5). Fifteen minutes after induction of anesthesia (50 mg/kg of pentobarbital), mice were intraplantarly injected with 15 μl of SB290157 (2 mg/ml) or PMX53 (1 mg/ml) or NS. Fifteen minutes later, the mice were intravenously injected with 100 μl of 6.25 mg/ml Evans Blue. Five minutes later, 7 μl of QKLI was administered by intraplantar injection in the hindpaws. Thirty minutes later, the mice were euthanized. The paw tissues were collected and weighed. Evans Blue was extracted by formamide at 60°C for 24 h. The OD values were read at 620 nm. The concentration of the dye in the paw tissues was calculated by the standard curve of the Evans Blue dye, and the dye content was expressed in microgram per gram of tissue. \*\**P* \< 0.01 *vs.* QKLI alone. **(D)** SB290157 could block QKLI-induced anaphylaxis (n = 8). The mice were pretreated with propranolol (intravenously, i.v., 35 μg/mouse) 10 min after intraperitoneally injected with SB290157 (a C3a antagonist, 30 mg/kg). Twenty minutes later, the mice were intraperitoneally challenged with QKLI (100 μl/mouse). Thirty minutes later, the rectal temperature was measured. ^\#\#^ *P* \< 0.01 *vs.* NS and \*\**P* \< 0.01 *vs.* QKLI alone. QKLI, Qing-Kai-Ling Injection; NA-IHR, non-allergic IHR; NS, normal saline.](fphar-10-01524-g004){#f4}

To our knowledge, anaphylatoxin C3a or C5a can activate mast cells to secrete histamine ([@B15]). Perhaps the QKLI-IHR is mediated by the activated complement. Accordingly, we used a C3a antagonist (SB290157) and a C5a antagonist (PMX53) to antagonize QKLI-induced vascular permeability increase. The result showed that SB290157, but not PMX53, significantly attenuated QKLI-induced Evans Blue extravasation ([**Figure 4C**](#f4){ref-type="fig"}). Consistently, in an anaphylactic shock assay, QKLI-induced anaphylaxis could also be countered by SB290157 ([**Figure 4D**](#f4){ref-type="fig"}), showing QKLI-caused NA-IHR was attributed to C3a, rather than C5a.

Isatidis Radix Is Responsible for QKLI-IHR {#s3_5}
------------------------------------------

To identify the main constituent(s) causing QKLI-IHR, all intermediate fractions in QKLI, including four extracts (F1--F4) and three compounds (cholic acid, hyodeoxycholic acid, and baicalin), were ready according to the Chinese Pharmacopoeia ([@B24]), and respectively evaluated their potential ability to cause IHRs. As a result, at their equivalent concentrations in QKLI, only F3 (Isatidis Radix) markedly caused Evans Blue leakage into the paw after the first intraplantar injection ([**Figure 5A**](#f5){ref-type="fig"}), and other fractions could not increase vasopermeability (data not shown). To confirm the above finding, QKLI without F3 (F3-free QKLI) and QKLI (self-QKLI) were prepared (235 mg F1, 275 mg F2, 3.02 g F3, 530 mg F4, 325 mg cholic acid, 375 mg hyodeoxycholic acid, and 500 mg baicalin were dissolved in water for injection to make 100 ml, pH 7.4). In agreement with commercial QKLI, self-QKLI, rather than F3-free QKLI, also potently induced hindpaw Evans Blue extravasation ([**Figure 5B**](#f5){ref-type="fig"}). These results indicated that Isatidis Radix was the crime culprit of QKLI-IHR. This finding, together with complement activation mechanism of QKLI-IHR, urged us to use a C3a antagonist SB290157 for the next experiment. Not surprisingly, SB290157 significantly weakened F3-caused Evans Blue leakage into the paw ([**Figure 5C**](#f5){ref-type="fig"}). *In vitro* results also showed that QKLI and F3 directly activated C3 in a concentration-dependent manner ([**Figure 5D**](#f5){ref-type="fig"}) with the half effective concentration (EC~50~) values of 0.69% and 218.6 μg/ml, respectively.

![Isatidis Radix is responsible for QKLI-IHR. **(A)** F3 increased vasopermeability after the first intraplantar injection (n = 5). Fifteen minutes after induction of anesthesia (50 mg/kg of pentobarbital), mice were intraplantarly (left paw) injected with 7 μl of F3 (30.2 mg/ml). The right paws were injected with 7 μl of NS. Five minutes later, the mice were injected (i.v.) with 100 μl of 6.25 mg/ml Evans Blue. Thirty minutes later, the mice were euthanized. The paw tissues were collected and weighed. Evans Blue was extracted by formamide at 60°C for 24 h. The OD values were read at 620 nm. The concentration of the dye in the paw tissues was calculated by the standard curve of the Evans Blue dye, and the dye content was expressed in microgram per gram of tissue. ^\*\*^ *P* \< 0.01 *vs.* NS. **(B)** Representative image of Evans Blue extravasation of mouse paw induced by F3-free QKLI and self-QKLI. **(C)** F3-induced Evans Blue extravasation was attenuated by SB290157 (n = 5). ^\*\*^ *P* \< 0.01 *vs.* F3 alone. **(D)** QKLI and F3 directly activated C3 *in vitro*. The plasma was treated with test substances at the indicated concentrations and C3a-desArg level was determined by a commercial ELISA kit. Tween-80 was used as a positive control. ^\*\*^ *P* \< 0.01 *vs.* NS.](fphar-10-01524-g005){#f5}

To search for the definite ingredients for QKLI-IHR, we also tested nine availably characteristic compounds of Isatidis Radix, including indirubin, epigoitrin, DL-goitrin, 2-(1H-indol-3-yl)acetonitrile, indigo, chlorogenic acid, (1-methoxy-1H-indol-3-yl) acetonitrile, caffeic acid, and geniposide. Regrettably, none of them induced vasopermeability increase at a dose of 10 mM which is far higher than their equivalent concentrations in QKLI (data not shown), indicating that the 9 compounds are not the material basis of QKLI-IHR.

Discussion {#s4}
==========

IHRs can be divided into allergic- and as non-allergic-mediated ([@B13]). Most of QKLI-IHRs are likely to be non-allergic owing to the fact that QKLI-IHRs commonly occurred after the first treatment clinically ([@B35]), but allergic-mediated IHRs cannot be ruled out yet. There are two pathways that can lead to allergic-mediated IHRs: the IgE-mediated classic pathway and the IgG-mediated alternative pathway ([@B25]). Although the kinetics and clinical features of these two types are generally similar, IgE is easier to cause allergy because considerably more antibody and antigen are required to induce IgG-mediated allergy ([@B26]). Thus, the potentiality of IgE-mediated allergy by QKLI was firstly evaluated. To amplify the possible Th2 response, an aluminum adjuvant was used during mouse immunization. Serum tIgE level was measured after 5 weeks, and during this period the tIgE concentration should be peak and stable ([@B9]). By contrast to ST, QKLI did not increase serum tIgE under our experimental conditions ([**Figure 2A**](#f2){ref-type="fig"}), suggesting that it seems very unlikely to induce allergy by QKLI.

Consistent with clinical practice, QKLI can significantly contribute to NA-IHRs in both local (increase of microvascular permeability, [**Figure 2B**](#f2){ref-type="fig"}) and systemic (induction of hypothermia, [**Figure 3**](#f3){ref-type="fig"}) models. A histamine H1 receptor antagonist triprolidine can counter QKLI-induced NA-IHRs ([**Figure 3**](#f3){ref-type="fig"}). Histamine is primarily secreted by mast cells ([@B4]), suggesting that QKLI-IHRs might be mast cell-dependent. Mast cells can be activated by basic secretagogues (e.g., C48/80 or substance P) through a single receptor Mas-related gene receptor MrgprX2 ([@B21]), which raises the question whether that QKLI possesses the characteristics of basic secretagogues. For the reason, two cells (human mast cell line LAD2 and mouse peritoneal mast cells) with the specific receptor MrgprX2 or MrgprB2 were used ([@B27]). As a result, QKLI could not induce two cells degranulation ([**Figure 4A**](#f4){ref-type="fig"}). In C48/80-simulated LAD2 cells, QKLI even dampened β-hexosaminidase release ([**Figure 4B**](#f4){ref-type="fig"}), indicating that QKLI induces NA-IHR via an indirect rather than direct effect on mast cells.

The complement-derived anaphylatoxins C3a and C5a can activate mast cells by binding to their respective receptors C3aR and C5aR and consequently lead to degranulation and histamine secretion ([@B1]). QKLI-IHR was countered by a C3a antagonist SB290157 ([**Figures 4C**](#f4){ref-type="fig"}, [**D**](#f4){ref-type="fig"}), rather than C5a antagonist (PMX53), demonstrating that QKLI might directly activate complement C3 in circulatory system. Indeed, QKLI directly activated C3 in human serum *in vitro* with an EC~50~ value of 0.69% ([**Figure 5D**](#f5){ref-type="fig"}). According to the Chinese Pharmacopoeia ([@B24]), QKLI consists of seven fractions including four extracts and three compounds, of which F3 (the extract of Isatidis Radix), rather than other six fractions, potently induced Evans Blue extravasation in mouse hindpaw. This effect was disappeared in F3-free QKLI ([**Figures 5A**](#f5){ref-type="fig"}, [**B**](#f4){ref-type="fig"}) and also could be countered by the C3a antagonist ([**Figure 5C**](#f5){ref-type="fig"}), indicating that the crime culprit for QKLI-IHR is Isatidis Radix, a non-ANP-derived material. Some components from Isatidis Radix, including baicalin and the other two botanical drugs (Gardeniae Fructus and Lonicerae japonicae Flos), were identified by HPLC ([**Figure 1**](#f1){ref-type="fig"}). Next, we determined the effects of the available components from Isatidis Radix on the vascular permeability. Regrettably, the main ingredient(s) responsible for the QKLI-IHR was not found out. Accordingly, further chemical research is needed to obtain more new components of Isatidis Radix for identifying its pseudoallergic substances. In fact, QKLI-IHR is complement activation-related pseudoallergy (CARPA) ([@B29]), which was also commonly triggered by many chemical intravenous preparations, such as intravenous iron ([@B12]), radiocontrast agents ([@B28]), etc. Obviously, as an extract of ANP, QKL induces an emerging CARPA which resulted from the addition of Isatidis Radix and the change of traditional drug-delivery way (p.o.). In the current situation, the pseudoallergic potency of Isatidis Radix should be emphatically monitored because it determines the intensity of QKLI-IHR.

In conclusion, this is the first study to show that QKLI-IHR is CARPA, rather than an IgE-mediated allergy. QKLI causes C3 activation, and might consequently activate mast cells to release histamine, which is a principal effector of its NA-IHR. In the seven fractions of QKLI, Isatidis Radix is primarily responsible for QKLI-IHR. Further explorations are required to identify the basis material associated with Isatidis Radix-induced NA-IHR. Our study suggests a potential therapeutic strategy for the prophylaxis and treatment of QKLI-IHR.
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